Galaxy Digital Inc. Class A Common Stock vs Natera Inc. Common Stock — how do they compare? Galaxy Digital Inc. Class A Common Stock trades at $17.29 (market cap $3.48B), while Natera Inc. Common Stock trades at $393.93 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 16.4× Galaxy Digital Inc. Class A Common Stock's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Galaxy Digital Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Galaxy Digital Inc. Class A Common Stock for 2 Days and Natera Inc. Common Stock for 0 Days on average.
| GLXY | NTRA | |
|---|---|---|
Market Cap | $3.48B | $57.03B |
Volume | 9,375,439 | 1,131,157 |
Sector | Financials | Health |
52-Week High | $42.86 | $425.64 |
52-Week Low | $16.84 | $179.42 |
Typical Hold Time | 2 Days | 0 Days |
Enterprise Value | $5.93B | $56.18B |
Signals from Pluang's Aura AI — not financial advice
Galaxy Digital (GLXY) trades at $19.71, down 0.81% with bearish technical signals but strong analyst support. The company reported Q2 2026 EPS of -$0.09, beating expectations, though revenue declined to $57.4B in 2026 with a net loss of -$315M. Recent news includes a Citigroup upgrade to Buy and upcoming Q3 earnings on October 27, 2026.
Despite current losses, analyst consensus is bullish with an $38.20 price target (81.8% Buy ratings). Key risks include negative profit margins and cash flow challenges, but institutional buying and strategic partnerships provide upside potential if earnings improve.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Galaxy provides digital-asset financial services and data center infrastructure. Its digital-assets business includes trading, asset management, investment banking, staking, tokenization, and custody technology.
Read more on GLXY →Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →